EU Business News- Q3 2025 Best Marine Biotechnology Company 2025 – Norway Based in Northern Norway, Marealis is a biotech company operating at the intersection of sustainability, innovation, and human wellness – turning overlooked marine byproducts into highvalue health and nutrition solutions. A leader in its field, the company specialises in utilising shrimp shells and heads – materials that would otherwise go to waste – and transforming them into powerful ingredients for food, feed, and supplements. Following Marealis’ recent recognition in the Scandinavian Business Awards 2025, we caught up with CEO Andreas Semmingsen to find out more. Promising upcycled marine innovation, natural efficacy, and proven health benefits, Marealis operates within three core areas of business: ingredients, standing as one of the world’s leading producer of Arctic shrimp shell powder with more than 500 metric tons delivered annually; consumer health, marketing and distributing its flagship nutraceutical PreCardix® through Canadian subsidiary Marealis Health; and global B2B supplements, scaling internationally through partnerships designed to introduce science-backed natural health products to new markets across the globe. At its core, Marealis exists to create value from the ocean – not just economically but sustainably and responsibly. The company is on a mission to lead the way in marine-based health innovation, helping people to live longer and happier lives while reducing industry waste through sustainable methodologies. To achieve this mission, Marealis upcycles all shrimp shells and heads from parent company Stella Polaris, fully utilising more than 5,000 tons annually. What’s more, every product the company launches is rooted in rigorous scientific validation, driven by Marealis’ commitment to science and quality. Its flagship product is PreCardix®, a natural, blood pressure supplement made from patented bioactive marine peptides – clinically proven, safe, and backed by Norwegian science. A unique offering in the cardiovascular health category, it follows therapeutic dosing aligned with clinical research, a rare practice in the natural health product space. PreCardix® is already helping thousands of Canadians manage their blood pressure and cardiovascular health naturally. In 2025 and beyond, Marealis aims to help even more people by expanding PreCardix® into new markets, and launching additional products on healthy aging and longevity. “We’re proud to say we’re not just following industry trends – we’re setting them,” Andreas told us. “Marealis is at the forefront of the marine byproduct innovation movement. What began as a niche idea – upcycling shrimp shells into functional ingredients – is now becoming an emerging global standard, with marine byproducts increasingly being utilised across sectors. We’re leading the way with patented innovation, high-end health products, and an uncompromising focus on sustainability and quality. We believe the future of marine biotech lies in turning waste into value. And we’re already proving that the future is here.” This exceptional work is made possible by what the Marealis team calls the Artic Advantage. Northern Norway is rich in fishery and aquaculture knowledge that feeds directly into biotech manufacturing and also ensures that the company maintains strategic access to pristine raw material, with Arctic shrimp that are fresher, cleaner, and superior in quality. Not only that, but the region nurtures innovation with a supportive ecosystem and world-class research and development capabilities, allowing Marealis to collaborate with institutions such as Nofima and the Arctic University of Tromsø in its R&D phases, while receiving grants from Innovation Norway that have played key parts in its product development and international expansion. This location has been instrumental in Marealis’ growth, enabling the team to move faster and aim higher. Continuing on this fast-moving trajectory, 2025 and 2026 are shaping up to be transformative years for Marealis. Looking ahead, the company has a number of exciting plans in the works, including the expansion of PreCardix® in the global market through strategic partnerships; strengthening its position as a global leader in Arctic shrimp shell powder; and launching new marine-based health products that are focused on longevity and healthy aging, in collaboration with fellow Norwegian innovators. Ultimately, Marealis hopes to see a global shift towards more daring innovations within marine biotech – projects that bring real impact and value, not just incremental change and raw material utilisation. The company can see the untapped potential of every shrimp shell, believing that science can transform byproducts into life-changing solutions. “We want the world to know that ‘Science from the Arctic Sea’ is more than a slogan – it’s our foundation,” Andreas concluded. “From cardiovascular support to sustainable ingredient supply, our work brings natural health solutions from Norway to the world. We’re honoured to be recognised as Norway’s Best Marine Biotechnology Company 2025. This award affirms our belief that doing business responsibly – while thinking globally – can create meaningful, measurable change.” Contact: Andreas Semmingsen Company: Marealis AS Web Address: www.marealis.com & www.precardix.ca May25150 Marealis: Pioneering Marine Biotechnology from the Arctic Sea
RkJQdWJsaXNoZXIy NTY1MjM3